Menu Search
Equities

Transcenta Holding Ltd

6628:HKG

Transcenta Holding Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.04
  • Today's Change0.04 / 4.00%
  • Shares traded143.00k
  • 1 Year change-73.87%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Transcenta Holding Ltd's revenues fell -47.15% from 101.89m to 53.85m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 406.75m to a larger loss of 462.57m.
Gross margin26.02%
Net profit margin-1,606.19%
Operating margin-1,541.92%
Return on assets-21.08%
Return on equity-33.53%
Return on investment-29.77%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Transcenta Holding Ltd fell by 349.42m. However, Cash Flow from Investing totalled 57.47m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 358.04m for operations while cash used for financing totalled 47.20m.
Cash flow per share-0.8336
Price/Cash flow per share--
Book value per share2.46
Tangible book value per share0.9114
More ▼

Balance sheet in CNYView more

Transcenta Holding Ltd has a Debt to Total Capital ratio of 28.26%, a higher figure than the previous year's 5.20%.
Current ratio1.08
Quick ratio1.04
Total debt/total equity0.3939
Total debt/total capital0.2826
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.